Page 7 - PHESGO (PERTUZUMAB-TRASTUZUMAB) - Product Monograph

2.3. Fixed-dose SC combination of trastuzumab and pertuzumab:
A new way to approach HER2 + breast cancer treatment

 Giving you the Ьenefits of PERJEТA and Herceptin in one ready-to-use, fixed-
®
®
dose treatment for SC injection. 35,36,38,39

Administration in minutes, not hours 35,36,39

Loading doses (max)
P + H IV 150 420
PH FDC SC 8 30
Maintainence doses (max) P + H IV infusion PH FDC SC administration
P + H IV 90 180
Observation time
PH FDC SC 5 15
0 40 80 120 160 200 240 280 320 360 400 440 480 520 560 600
Time (minutes)

2.4. Liberating staff to use their time as they choose

 Based on experience with trastuzumab SC, using SC formulations can

free up as much as 70% of active HCP time. 37,40-42

Time savings were projected at an average of
5 hours per patient per treatment course,

potentially increase when two treatments are
given together 37

How much time saved could that mean for your centre?

 In the PHranceSCa study, HCPs saw potential benefits of fixed-dose SC
combination of trastuzumab and pertuzumab with respect to staff time and

efficiency across all stages of care. 43

77% agreed that it results in less drug wastage when using FDC

95% agreed SC administration takes least time from start to finish
vs IV

79% agreed fixed-dose SC combination of trastuzumab and
pertuzumab was the best option for optimising patient care
within their treatment site

M-AE-00000086 7